List view / Grid view
CPhI Worldwide, organised by UBM EMEA, today announced the findings of Part II of its 2015 annual report, entitled, ‘Quality, metrics and continuous processing’, ahead of CPhI Worldwide 2015 in Madrid.
30 September 2015 | By Victoria White
The results confirm that Ofev has a long-term effect on slowing IPF disease progression and has a manageable side effect profile...
30 September 2015 | By Victoria White
Astellas has obtained worldwide rights to commercialise Chromocell's lead compound, CC8464 - an oral, peripherally-acting inhibitor of NaV1.7...
29 September 2015 | By Victoria White
This first operation is a major milestone in the London Project to Cure Blindness, which was established 10 years ago with the aim of curing vision loss in patients with wet AMD...
29 September 2015 | By Victoria White
Infants received a significant bolus of all anti-RSV antibodies via transplacental transfer. As such, the RSV F Vaccine demonstrates the potential to protect infants when they are most at risk of infection...
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
29 September 2015 | By Victoria White
Advanced targeted therapies now account for 60% of the drugs under development for colorectal cancer...
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
CAMO Software, leaders in multivariate data analysis software, and Stat-Ease, Inc., a leading supplier of design of experiments (DOE) software and services, have released a software bundle for multivariate data analysis and design of experiments; The Unscrambler® X Design-Expert® Upgrade...
Lilly and Incyte have announced positive top-line results of a Phase 3 study evaluating the safety and efficacy of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).
29 September 2015 | By Victoria White
Piramal Enterprises' Pharma Solutions division has set a target of becoming the market leader in ADCs contract commercialisation over the next five years...
29 September 2015 | By Victoria White
A pooled analysis from two Phase III studies showed a 38% reduction in risk of death in IPF patients who stayed on Esbriet treatment up to two years...
28 September 2015 | By Victoria White
A 24-year, Phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer can safely take HRT during or after their treatment.
28 September 2015 | By Victoria White
Roche's study met its primary endpoint, showing treatment with ocrelizumab significantly reduced the progression of clinical disability...
28 September 2015 | By Victoria White
The results of the study, involving nearly 14,000 patients, may lead to new insights regarding the use of aspirin in gastrointestinal cancer...
